[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 43 of about 43
1. El-Attar HA, Ragab MS, Sheta MI, Ahmed AS: Hepatocyte growth factor in Egyptian females with breast benign lumps and cancers. Asian Pac J Cancer Prev; 2010;11(4):893-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocyte growth factor in Egyptian females with breast benign lumps and cancers.
  • OBJECTIVE: Estimation of the plasma level of HGF in females with benign breast lumps or breast carcinomas and correlating levels with important prognostic parameters.
  • SUBJECTS: Sixty eight adult premenopausal females were divided into control group of fifteen healthy volunteers and fifty-three patients subdivided into fifteen with benign breast lumps and thirty-eight with breast carcinomas.
  • METHODS: A thorough clinical examination, plain chest x-rays, ultrasonography of the abdomen and pelvis, pre- operative fine needle aspiration cytology, estimation of fasting serum glucose, urea, creatinine and uric acid levels, alanine aminotransferase activities, C-reactive protein, HGF level and histopathological examination of the breast masses were performed.
  • RESULTS: Significant increase in HGF levels was found in patients with benign breast lumps and in breast cancer patients when each was compared to controls and when cancer patients were compared to the benign breast lumps group.
  • CONCLUSION: The serum level of HGF is an independent prognostic indicator for breast cancer.
  • [MeSH-major] Breast Neoplasms / blood. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / blood. Carcinoma, Ductal, Breast / pathology. Fibroadenoma / blood. Hepatocyte Growth Factor / blood
  • [MeSH-minor] Age Factors. Egypt. Female. Fibrocystic Breast Disease / blood. Humans. Inflammation / blood. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Burden

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21133597.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


2. Cîmpean AM, Raica M, Nariţa D: Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast. Rom J Morphol Embryol; 2005;46(2):123-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast.
  • PURPOSE: Our aim was to investigate the distribution of CD34 and smooth muscle cell actin positive myofibroblasts in the stroma of the normal mammary gland, benign and malignant tumors.
  • METHODS: Our study included 112 female patients with suspect breast masses obtained by surgery or biopsy.
  • RESULTS: We have found normal breast tissue, sclerosing adenosis, fibroadenomas, fibrocystic diseases, phyllodes tumor, DCIS, ductal invasive, lobular, squamous, medullary, mucinous, and papillary carcinomas.
  • All the normal breast tissues and most of benign lesions were positive for CD34 and negative for SMA.
  • The exceptions were represented by a case of fibroadenoma and the phyllodes tumor, with CD34 positivity and a focal acquisition of SMA; fibrocystic disease with associated apocrine metaplasia adjacent to a squamous carcinoma with loss of CD34 expression and focal acquisition of SMA.
  • CONCLUSIONS: Although there were some exceptions especially when one of the two markers was interpreted separately and in some cases associated with sclerotic stroma, we conclude that the combined expression of CD34 and a-SMA is of potential diagnostic value in the distinction between benign and malignant tumors in some difficult cases.
  • [MeSH-major] Actins / analysis. Antigens, CD34 / analysis. Breast Neoplasms / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Biopsy. Carcinoma, Ductal / pathology. Female. Fibrocystic Breast Disease / pathology. Humans. Middle Aged. Neoplasm Invasiveness. Smad Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286998.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Smad Proteins
  •  go-up   go-down


3. Grenier J, Delbaldo C, Zelek L, Piedbois P: [Phyllodes tumors and breast sarcomas: a review]. Bull Cancer; 2010 Oct;97(10):1197-207
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumors and breast sarcomas: a review].
  • Phyllodes tumors and sarcomas of the breast are non-epithelial tumors of the breast.
  • Phyllodes tumors are benign tumors, tumors of intermediate malignancy or malignant tumors.
  • The differential diagnosis with a very proliferant fibroadenoma may be difficult.
  • Breast sarcomas are even rarer.
  • In some situations, a conservative treatment can be discussed, based on tumor size, grade and volume of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology. Sarcoma / pathology
  • [MeSH-minor] Female. Hemangiosarcoma / pathology. Hemangiosarcoma / secondary. Hemangiosarcoma / therapy. Humans. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855241.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Sabitha, Suneetha, Mohanty S, Rao P: Serum anti - TPO levels in benign and malignant breast tumors. Indian J Clin Biochem; 2009 Jul;24(3):266-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum anti - TPO levels in benign and malignant breast tumors.
  • Breast cancer is a hormone dependent neoplasm.
  • Conflicting results regarding the clinical correlation between breast cancer and thyroid diseases have been reported.
  • The objective of this study was to determine the association of anti - TPO levels in patients having complaints of a lump in breast.
  • Serum samples and Fine needle aspiration cytology (FNAC) samples were collected from 31 female patients with a lump in breast between the age group of 20-75 years.
  • FNAC results of others (n=26) were reported as fibroadenoma whose anti - TPO levels were less than the controls.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Med J. 1976 Jan 31;1(6004):257-9 [1082357.001]
  • [Cites] Br J Cancer. 1984 Jan;49(1):87-92 [6691901.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1232-3 [7962313.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):937-41 [8772554.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Mar;81(3):990-4 [8772562.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2711-6 [9709936.001]
  • [Cites] N Engl J Med. 2006 Jun 29;354(26):2783-93 [16807415.001]
  • [Cites] Indian J Clin Biochem. 2008 Jul;23(3):279-82 [23105770.001]
  • [Cites] Tumori. 2003 Sep-Oct;89(5):523-8 [14870777.001]
  • [Cites] Jpn J Cancer Res. 1999 Sep;90(9):922-7 [10551319.001]
  • [Cites] J Endocrinol Invest. 2000 Jan;23(1):42-3 [10698051.001]
  • [Cites] Jpn J Cancer Res. 2001 May;92(5):483-7 [11376555.001]
  • [Cites] Internist (Berl). 2003 Apr;44(4):396-402, 404-8, 410-1 [12914397.001]
  • (PMID = 23105847.001).
  • [ISSN] 0970-1915
  • [Journal-full-title] Indian journal of clinical biochemistry : IJCB
  • [ISO-abbreviation] Indian J Clin Biochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453311
  • [Keywords] NOTNLM ; Breast cancer / FNAC / anti — TPO
  •  go-up   go-down


5. Khoo JJ, Alwi RI, Abd-Rahman I: Myoid hamartoma of breast with chondroid metaplasia: a case report. Malays J Pathol; 2009 Jun;31(1):77-80
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoid hamartoma of breast with chondroid metaplasia: a case report.
  • Breast hamartoma is an uncommon poorly recognised benign breast neoplasm.
  • Hamartoma displaying marked smooth muscle components known as myoid hamartoma of the breast is a much rarer entity.
  • We present a case of myoid hamartoma of breast with chondroid differentiation in a 46-year-old woman.
  • The painless breast lump was circumscribed and mammography showed a well-encapsulated large, dense mass with no calcification.
  • Core needle biopsy was reported as fibroadenoma.
  • The various immuno-histochemical staining as well as the cyto-histological changes encountered in myoid hamartomas are discussed with clinical, radiological and pathological correlation to differentiate it from other benign and malignant breast lesions.
  • [MeSH-major] Breast Diseases / pathology. Hamartoma / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Biomarkers / metabolism. Breast Neoplasms / diagnosis. Cartilage / pathology. Cell Differentiation. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Humans. Immunohistochemistry. Metaplasia / pathology. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694319.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


6. Sheen-Chen SM, Liu YW, Eng HL, Chou FF: Serum levels of hepatocyte growth factor in patients with breast cancer. Cancer Epidemiol Biomarkers Prev; 2005 Mar;14(3):715-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of hepatocyte growth factor in patients with breast cancer.
  • However, there is still limited knowledge about the role of HGF in breast cancer.
  • This study was designed with the aim to elucidate the possible relationship between the preoperative circulating soluble HGF and breast cancer.
  • MATERIALS AND METHODS: One hundred twenty-four consecutive patients with invasive breast cancer undergoing surgery were prospectively included and evaluated.
  • The control group consisted of 35 patients with benign breast tumor (20 with fibrocystic disease and 15 with fibroadenoma).
  • RESULTS: The mean value of serum soluble HGF in patients with invasive breast cancer was 529.05 +/- 123.33 pg/mL and that of control group was 343.00+/- 31.03 pg/mL and the difference was significant (P < 0.001).
  • Thus, preoperative serum soluble HGF levels might reflect the severity of invasive breast cancer and deserve further evaluation.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / pathology. Hepatocyte Growth Factor / blood. Neoplasm Invasiveness
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Middle Aged. Neoplasm Staging. Prospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767355.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


7. Reis-Filho JS, Steele D, Di Palma S, Jones RL, Savage K, James M, Milanezi F, Schmitt FC, Ashworth A: Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue. Mod Pathol; 2006 Feb;19(2):307-19
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and significance of nerve growth factor receptor (NGFR/p75NTR) in normal, benign and malignant breast tissue.
  • NGFR expression was immunohistochemically analysed in normal breast tissue and in 140 benign, biphasic and preinvasive breast lesions, in 22 tumours with myoepithelial differentiation and in two cohorts of breast cancer patients: a series of 245 invasive breast carcinomas studied with tissue microarrays and 37 high-grade invasive ductal carcinomas with basal-like immunophenotype.
  • Myoepithelial cells of benign proliferations and pre-invasive lesions were consistently positive for NGFR.
  • Positivity for NGFR was observed in 11 out of 245 (4.5%) breast carcinomas, nine out of 20 (45%) metaplastic breast carcinomas and 14 out of 37 (38%) basal-like breast carcinomas.
  • This study demonstrates the usefulness of NGFR as a new adjunct marker to identify myoepithelial cells in preinvasive lesions and myoepithelial differentiation in breast carcinomas.
  • Furthermore, provisional data in a small number of basal-like breast carcinomas suggest that NGFR may identify a subgroup of basal-like breast carcinomas with good prognosis.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Nerve Tissue Proteins / analysis. Receptors, Growth Factor / analysis
  • [MeSH-minor] Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Lobular / metabolism. Carcinoma, Lobular / pathology. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Fibrocystic Breast Disease / metabolism. Fibrocystic Breast Disease / pathology. Humans. Immunohistochemistry. Keratin-14. Keratin-5. Keratin-6. Keratins / analysis. Myoepithelioma / metabolism. Myoepithelioma / pathology. Neoplasm Invasiveness. Receptors, Estrogen / analysis. Receptors, Nerve Growth Factor. Receptors, Progesterone / analysis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424897.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT14 protein, human; 0 / KRT5 protein, human; 0 / KRT6A protein, human; 0 / KRT6B protein, human; 0 / KRT6C protein, human; 0 / Keratin-14; 0 / Keratin-5; 0 / Keratin-6; 0 / NGFR protein, human; 0 / Nerve Tissue Proteins; 0 / Receptors, Estrogen; 0 / Receptors, Growth Factor; 0 / Receptors, Nerve Growth Factor; 0 / Receptors, Progesterone; 68238-35-7 / Keratins
  •  go-up   go-down


8. Calcaterra V, Coscia DR, Sgarell A, Burroni B, Podetta M, Andorno A, Ferrari A, Larizza D: Recurrence of giant juvenile breast fibroadenoma in a girl with Turner's syndrome. J Pediatr Endocrinol Metab; 2009 Mar;22(3):281-3
MedlinePlus Health Information. consumer health - Turner Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of giant juvenile breast fibroadenoma in a girl with Turner's syndrome.
  • Pathological breast conditions are rare in childhood and adolescence.
  • The spectrum of breast disease in pediatric patients is different from that in adults and most lesions are benign.
  • Fibroadenomas are the most common type of breast tumor in adolescent girls and young women.
  • We report here a case of recurrent juvenile giant breast fibroadenoma in a girl with Turner's syndrome.
  • [MeSH-major] Breast Neoplasms / pathology. Fibroadenoma / pathology. Neoplasm Recurrence, Local / pathology. Turner Syndrome / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19492586.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Rego MF, Navarrete MA, Facina G, Falzoni R, Silva R, Baracat EC, Nazario AC: Analysis of human mammary fibroadenoma by Ki-67 index in the follicular and luteal phases of menstrual cycle. Cell Prolif; 2009 Apr;42(2):241-7
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of human mammary fibroadenoma by Ki-67 index in the follicular and luteal phases of menstrual cycle.
  • OBJECTIVES: Fibroadenoma is the most common benign mammary condition among women aged 35 or younger.
  • Expression of Ki-67 antigen has been used to compare proliferative activity of mammary fibroadenoma epithelium in the follicular and luteal phases of the menstrual cycle.
  • RESULTS: Both groups were found to be homogeneous relative to age, menarche, body mass index, previous gestation, parity, breastfeeding, number of fibroadenomas, family history of breast cancer and tabagism.
  • CONCLUSION: Our findings revealed that proliferative activities in the mammary fibroadenoma epithelium did not present a statistically significant difference in the follicular and luteal phases.
  • The present study contributes to clarifying that fibroadenoma is a neoplasm and does not undergo any change in the proliferative activity during the menstrual cycle.
  • [MeSH-major] Breast Neoplasms / pathology. Cell Proliferation. Fibroadenoma / pathology. Follicular Phase / metabolism. Ki-67 Antigen / metabolism. Luteal Phase / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Breast Feeding / statistics & numerical data. Female. Humans. Obesity / complications. Progesterone / blood. Tobacco Use Disorder / complications. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19317807.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


10. Wang ZC, Buraimoh A, Iglehart JD, Richardson AL: Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays. Breast Cancer Res Treat; 2006 Jun;97(3):301-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays.
  • Phyllodes tumors of the breast are biphasic stromal and epithelial tumors histologically similar to benign fibroadenomas, but with a neoplastic stromal component.
  • In contrast to fibroadenoma, phyllodes tumors can recur and be locally aggressive or be malignant.
  • [MeSH-major] Breast Neoplasms / genetics. Fibroadenoma / genetics. Loss of Heterozygosity. Neoplasms, Multiple Primary / genetics. Neoplasms, Second Primary / genetics. Oligonucleotide Array Sequence Analysis. Phyllodes Tumor / genetics. Polymorphism, Single Nucleotide
  • [MeSH-minor] Cell Transformation, Neoplastic / genetics. DNA, Neoplasm / genetics. Epithelial Cells / pathology. Female. Gene Expression Profiling. Genome, Human. Humans. Stromal Cells / pathology

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16791486.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / NCI P50 CA89393-01
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


11. Chowdary MV, Kalyan Kumar K, Mathew S, Rao L, Krishna CM, Kurien J: Biochemical correlation of Raman spectra of normal, benign and malignant breast tissues: a spectral deconvolution study. Biopolymers; 2009 Jul;91(7):539-46
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biochemical correlation of Raman spectra of normal, benign and malignant breast tissues: a spectral deconvolution study.
  • The aim of this study was to understand and correlate spectral features and biochemical changes in normal, fibroadenoma and infiltrating ductal carcinoma of breast tissues using Raman spectra that were part of the spectroscopic models developed and evaluated by us earlier.
  • This study has revealed that fat (1301 and 1440 cm(-1)), collagen (1246, 1271, and 1671 cm(-1)) and DNA (1340 and 1480 cm(-1)) bands have strong presence in normal, benign and malignant breast tissues, respectively.
  • Thus the finding of this study further demonstrates the efficacy Raman spectroscopic approaches in diagnostic applications as well as in understanding molecular phenomenon in breast cancers.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Spectrum Analysis, Raman
  • [MeSH-minor] Collagen / chemistry. DNA, Neoplasm / chemistry. Female. Humans. Lipids / chemistry. Neoplasm Proteins / chemistry. Vibration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley Periodicals, Inc.
  • (PMID = 19226625.001).
  • [ISSN] 0006-3525
  • [Journal-full-title] Biopolymers
  • [ISO-abbreviation] Biopolymers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Lipids; 0 / Neoplasm Proteins; 9007-34-5 / Collagen
  •  go-up   go-down


12. Dillon MF, Quinn CM, McDermott EW, O'Doherty A, O'Higgins N, Hill AD: Needle core biopsy in the diagnosis of phyllodes neoplasm. Surgery; 2006 Nov;140(5):779-84
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Needle core biopsy in the diagnosis of phyllodes neoplasm.
  • BACKGROUND: Accurate identification of phyllodes neoplasms without surgical intervention is difficult, reducing the ability to manage "benign" lumps non-operatively and impacting on the open benign biopsy rate.
  • Needle core biopsy is considered to be a highly accurate technique in the diagnosis of breast carcinoma.
  • Its accuracy in the diagnosis of phyllodes neoplasm has not been established.
  • RESULTS: Twenty-three patients had phyllodes neoplasm on excisional biopsy with prior core biopsy findings as follows: phyllodes neoplasm (n=2), "equivocal" for phyllodes neoplasm (n=12), fibroadenoma (n=3), benign (n=6).
  • The false negative rate for phyllodes neoplasm was therefore 39% (n=9/23).
  • Of the total biopsy series, 35 patients had a core biopsy suggesting the possibility of phyllodes neoplasm.
  • Of these, 32% (n=11) were found to be phyllodes neoplasm on excision, 3% (n=1) phyllodes neoplasm with breast carcinoma, 6% (n=2) breast carcinoma, and 3% (n=1) sarcoma.
  • When a preference for phyllodes neoplasm (n=4) was stated on the equivocal core biopsies, excision correlated with the stated preference; this correlation also occurred in 90% (n=9/10) of core biopsies where fibroadenoma was favored.
  • CONCLUSIONS: Needle core biopsy rarely produces a definite preoperative diagnosis of phyllodes neoplasm.
  • A diagnosis of fibroadenoma or equivocal phyllodes neoplasm on core biopsy should not prevent excision if clinical suspicion remains.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / diagnosis. Diagnostic Errors. Phyllodes Tumor / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084721.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Ravindra S, Suguna BV: Cytomorphology of tubular adenoma breast--a case report. Indian J Pathol Microbiol; 2006 Apr;49(2):267-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytomorphology of tubular adenoma breast--a case report.
  • Tubular adenoma a 'pure adenoma' is a benign neoplasm of breast presenting clinically like fibroadenoma.
  • [MeSH-major] Adenoma / pathology. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Fibroadenoma / pathology. Fibrocystic Breast Disease / pathology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16933735.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 7
  •  go-up   go-down


14. Tea MK, Asseryanis E, Kroiss R, Kubista E, Wagner T: Surgical breast lesions in adolescent females. Pediatr Surg Int; 2009 Jan;25(1):73-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical breast lesions in adolescent females.
  • PURPOSE: Breast diseases in teenage girls are fortunately uncommon, with most presenting masses being benign.
  • The aim of this study was to evaluate the histopathological results of breast lesions excised from adolescent females less than 19 years of age.
  • All data included the patient age, age of menarche, pregnancy, hormonal contraception, family history of breast cancer, size of the breast lesion and its histopathology following surgery.
  • RESULTS: Thirty-seven female patients with an average age of 16 years (ranging 12-18 years) were operated on for breast tumor and/or discharge.
  • Six patients had bilateral breast masses; thus, 43 breast lesions were evaluated following surgical excision.
  • Surprisingly, breast cancer was found in two cases.
  • Both patients were diagnosed with a noninvasive ductal carcinoma in situ (DCIS) within a fibroadenoma at the age of 16.
  • As breast neoplasm was found in two cases, a malignancy rate of 4.7% was observed.
  • The most common histologies were fibroadenoma (n=27) and fibrocystic disease (n=4).
  • CONCLUSION: The incidence of primary breast cancer in adolescent women is low.
  • However, our experience shows the need for compulsory excision of all breast masses and highlighting the importance of histopathological evaluation of all breast tumors including adolescents.
  • [MeSH-major] Breast Neoplasms / pathology. Fibrocystic Breast Disease / pathology
  • [MeSH-minor] Adolescent. Austria. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Child. Female. Fibroadenoma / pathology. Fibroadenoma / surgery. Genetic Predisposition to Disease. Humans. Mastectomy. Phyllodes Tumor / pathology. Phyllodes Tumor / surgery. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Surg Int. 2005 May;21(5):381-2 [15742186.001]
  • [Cites] N Engl J Med. 1994 Jul 7;331(1):10-5 [8202095.001]
  • [Cites] Eur J Pediatr Surg. 1998 Apr;8(2):67-70 [9617602.001]
  • [Cites] Diagn Cytopathol. 1992;8(2):137-46 [1314730.001]
  • [Cites] J Adolesc Health. 1998 Jul;23(1):3-6 [9648017.001]
  • [Cites] Can J Surg. 1985 Jul;28(4):372-4 [2990650.001]
  • [Cites] Eur J Cancer. 2003 Dec;39(18):2632-42 [14642925.001]
  • [Cites] Breast. 2001 Oct;10(5):399-404 [14965614.001]
  • [Cites] Semin Diagn Pathol. 1999 Aug;16(3):235-47 [10490200.001]
  • [Cites] Obstet Gynecol Clin North Am. 1992 Mar;19(1):91-102 [1584547.001]
  • [Cites] Pathology. 1998 Nov;30(4):419-21 [9839320.001]
  • [Cites] Pediatr Surg Int. 1999 Jul;15(5-6):427-8 [10415310.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):467-72 [17337650.001]
  • [Cites] J Pediatr Surg. 1994 Jan;29(1):48-51 [8120761.001]
  • [Cites] Indian J Pathol Microbiol. 2006 Oct;49(4):592-4 [17183868.001]
  • [Cites] Acta Chir Belg. 2006 Jul-Aug;106(4):400-4 [17017692.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):572-4 [15297206.001]
  • [Cites] Plast Reconstr Surg. 2007 Jul;120(1):13e-19e [17572540.001]
  • [Cites] J Adolesc Health. 1993 Jun;14(4):277-81 [8347638.001]
  • (PMID = 18985359.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Streckfus CF, Mayorga-Wark O, Arreola D, Edwards C, Bigler L, Dubinsky WP: Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast. Cancer Invest; 2008 Mar;26(2):159-67
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast.
  • OBJECTIVE: The objective of this study was to determine if protein-by-products secondary to cancer related oncogenes appear in the saliva of breast cancer patients.
  • One pooled specimen was from healthy women, another pooled specimen from women diagnosed with a benign breast tumor and the other one pooled specimen was from women diagnosed with ductal carcinoma in situ (DCIS).
  • Forty-nine proteins were differentially expressed between the healthy control pool and the benign and cancer patient groups.
  • Additionally, there may be salivary protein profiles that are unique to both DCIS and fibroadenoma tumors.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Fibroadenoma / metabolism. Neoplasm Proteins / metabolism. Saliva / metabolism. Salivary Proteins and Peptides / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18259946.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Salivary Proteins and Peptides
  •  go-up   go-down


16. Li EX, Wu YY, Shi F, Wu Y, Guo JJ, Dong DF: [Relationship between serum VEGF level and VEGF, COX-2 and MVD expression in breast cancer tissues]. Zhonghua Zhong Liu Za Zhi; 2007 Jul;29(7):522-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Relationship between serum VEGF level and VEGF, COX-2 and MVD expression in breast cancer tissues].
  • OBJECTIVE: To investigate the relationship between serum VEGF (sVEGF) level and VEGF, COX-2 and MVD expression in breast cancer, and to discuss their role in angiogensis of breast cancer.
  • METHODS: sVEGF level was detected by ELISA in 68 preoperative breast cancer, 35 benign breast disease and 20 healthy women.
  • The expression of VEGF, COX-2 and MVD was detected by immunohistochemical method in tissues of breast cancer and breast benign diseases, and to analyze the relationship of sVEGF, VEGF, COX-2 and MVD. RESULTS:.
  • (1) sVEGF level in preoperative breast cancers was 306.51 pg/ml (interquartile range from 190.44 to 442.04 pg/ml), in benign diseases was 150.82 pg/ml (interquartile range from 82.36 to 212.34 pg/ml), and in healthy control was 105.93 pg/ml (interquartile range from 78.54 to 157.77 pg/ml).
  • The sVEGF level of preoperative breast cancer group was significantly higher than that of breast benign disease group and healthy women (P = 0.001). (2) The VEGF expression positive rate in breast cancer (67.65%) was significantly higher than that in breast benign disease (44.12%) (P = 0.015).
  • The COX-2 expression positive rate in breast cancer (42.86%) was significantly higher than that in breast benign disease (11.43%) (P = 0.002). (3) the COX-2 expression positive rate in sVEGF high level patients (56.00%) was significantly higher than that in sVEGF normal level patients (11.11%) (P = 0.024), and MVD in sVEGF high level patients (27.32 +/- 3.40) was also higher than that in sVEGF normal level patients (15.31 +/- 6.16) (P = 0.011). (4) The sVEGF level (322.09 +/- 79.31) of 68 breast cancer patients whose VEGF was positive in breast cancer tissues was significantly higher than that in VEGF negative group (222.47 +/- 73.53) (P = 0.017). (5) The COX-2 expression positive rate in VEGF positive expression group (65.21%) was significantly higher than that in VEGF negative expression group (18.18%) (P = 0.017).
  • CONCLUSION: sVEGF level in breast cancer is significantly higher than that in breast benign disease and healthy women, and is correlated with the expression of COX-2 and MVD in breast cancer tissues.
  • [MeSH-major] Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Cyclooxygenase 2 / metabolism. Microvessels / pathology. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Female. Fibroadenoma / blood. Fibroadenoma / blood supply. Fibroadenoma / metabolism. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18069633.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


17. Li BJ, Huang XP, Wei WD, Wang JY, Su XD, Zhang X, Hong WS, Tang J, Zhang LJ, Long H, Yang MT, Rong TH: [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer]. Ai Zheng; 2005 Jun;24(6):735-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and clinical significance of cytokeratin 19 in bone marrow of patients with breast cancer].
  • BACKGROUND & OBJECTIVE: Breast cancer may undergo metastasis in early phase.
  • Distant metastasis, especially bone metastasis, may influence prognosis of breast cancer patients.
  • This study was designed to evaluate expression and clinical significance of cytokeratin 19 (CK19) in bone marrow of patients with breast cancer.
  • METHODS: Expression of CK19 mRNA in bone marrows of 65 breast cancer patients, 15 benign breast disease patients, and 8 healthy volunteers was detected by reverse transcription-polymerase chain reaction (RT-PCR).
  • Correlation of CK19 mRNA expression to clinicopathologic features of the 65 breast cancer patients was analyzed.
  • RESULTS: Positive rate of CK19 mRNA was 33.8% in the 65 breast cancer patients, and 0 in both benign breast disease patients and healthy volunteers.
  • CONCLUSIONS: CK19 mRNA may be used as a molecular marker to detect bone marrow micrometastasis in patients with breast cancer.
  • The detection may help to select proper therapy and predict prognosis of breast cancer patients.
  • [MeSH-major] Bone Marrow / metabolism. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Keratin-19 / biosynthesis
  • [MeSH-minor] Adult. Aged. Breast Neoplasms, Male / metabolism. Breast Neoplasms, Male / pathology. Carcinoembryonic Antigen / blood. Female. Fibroadenoma / blood. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15946491.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / RNA, Messenger
  •  go-up   go-down


18. Jayaram G, Elsayed EM, Yaccob RB: Papillary breast lesions diagnosed on cytology. Profile of 65 cases. Acta Cytol; 2007 Jan-Feb;51(1):3-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary breast lesions diagnosed on cytology. Profile of 65 cases.
  • OBJECTIVE: To analyze the cytologic features of nipple discharge and fine needle aspiration (FNA) cytologic smears from breast lesions reported as showing papillary features and to correlate them with histopathologic features.
  • STUDY DESIGN: The study group consisted of FNA smears and/or nipple discharge smears from 65 breast lesions diagnosed on cytology as duct papilloma, papillary lesion, fibrocystic condition, fibroadenoma, papillary neoplasm or papillary carcinoma.
  • There was an overlap in cytomorphologic features between papillary and nonpapillary benign lesions as well as between benign and malignant papillary neoplasms.
  • CONCLUSION: Overlap of cytologic features in nonneoplastic and neoplastic benign papillary lesions and between benign and malignant papillary neoplasms necessitates histologic evaluation in all cases diagnosed as papillary on cytology.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Papillary / pathology
  • [MeSH-minor] Biopsy, Fine-Needle. Diagnosis, Differential. Female. Fibroadenoma / pathology. Fibrocystic Breast Disease / pathology. Humans. Papilloma, Intraductal / pathology. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17328487.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Al-Thobhani AK, Raja'a YA, Noman TA, Al-Romaimah MA: Profile of breast lesions among women with positive biopsy findings in Yemen. East Mediterr Health J; 2006 Sep;12(5):599-604
MedlinePlus Health Information. consumer health - Breast Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Profile of breast lesions among women with positive biopsy findings in Yemen.
  • This study described the profile of breast pathology based on records from a reference histopathology laboratory in Yemen of 773 women with positive biopsy or mastectomy findings.
  • Benign lesions were found in 79.9% of cases.
  • Fibroadenoma was the most prevalent lesion (30.0%) with a mean age at presentation of 22.2 years, followed by fibrocystic disease (27.4%) and breast inflammation (13.1%).
  • [MeSH-major] Biopsy. Breast Neoplasms / epidemiology. Fibrocystic Breast Disease / epidemiology. Mastitis / epidemiology
  • [MeSH-minor] Adenoma / epidemiology. Adult. Age Distribution. Carcinoma, Ductal, Breast / epidemiology. Female. Fibroadenoma / epidemiology. Humans. Incidence. Mastectomy. Neoplasm Staging. Population Surveillance. Prevalence. Retrospective Studies. Risk Factors. Yemen / epidemiology

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17333799.001).
  • [ISSN] 1020-3397
  • [Journal-full-title] Eastern Mediterranean health journal = La revue de santé de la Méditerranée orientale = al-Majallah al-ṣiḥḥīyah li-sharq al-mutawassiṭ
  • [ISO-abbreviation] East. Mediterr. Health J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


20. Zhou S, Xu Z, Ling XF, Li QB, Xu YZ, Zhang L, Zhao HM, Wang LX, Hou KY, Zhou XS, Wu JG: [FTIR spectroscopic characterization of freshly removed breast cancer tissues]. Zhonghua Zhong Liu Za Zhi; 2006 Jul;28(7):512-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [FTIR spectroscopic characterization of freshly removed breast cancer tissues].
  • OBJECTIVE: To identify the FTIR spectroscopic characterization of breast cancer and explore the possibility of application of FTIR in differentiation of malignant and benign breast lesions.
  • METHODS: FTIR spectra of surgically removed fresh breast tissues were measured by spectrometer equipped with mid-infrared fiber optics and an ATR probe.
  • Peaks in the spectra were measured and relative intensity ratios were calculated and analyzed if there are significant differences between the spectra of malignant and benign breast lesions.
  • RESULTS: There were significant differences (P < 0.05) between the spectra of malignant breast cancers and benign breast tissues in the relative intensity ratios of different peaks (I1640/ I1550 and I1160/I1120 for protein structures; I1640/I1460 and I1550/I1460 for relative content of protein and lipid; I1460/I1400 for lipid structures; I1310/I1240 for nucleic acid).
  • CONCLUSION: FTIR spectroscopy could be a useful tool in clinical diagnosis of breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis. Spectroscopy, Fourier Transform Infrared / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast / chemistry. Breast / pathology. Female. Humans. Lipids / analysis. Middle Aged. Neoplasm Proteins / analysis. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147115.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Lipids; 0 / Neoplasm Proteins
  •  go-up   go-down


21. Eroğlu A, Sari A: Expression of c-kit proto-oncogene product in breast cancer tissues. Med Oncol; 2007;24(2):169-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-kit proto-oncogene product in breast cancer tissues.
  • BACKGROUND: The published results on expression of c-kit in benign and malignant breast tissues vary.
  • MATERIALS AND METHODS: The immunohistochemical expression of c-kit proto-oncogene product in 52 invasive breast cancer tissues and 16 benign breast tumor (fibroadenoma) tissues was studied using anti-c-kit proto-oncogene product antibody.
  • RESULTS: In breast cancer tissues, the mean IRS of c-kit proto-oncogene product expression was significantly increased compared to those of fibroadenoma (3.4 +/- 2 and 2.19 +/- 1.8, respectively,p = 0.035).
  • The mean IRS of c-kit expression was higher in the group comprising estrogen (ER) positive tumor than in the group of ER negative (4.1 +/- 2.1 and 2.7 +/- 1.8, respectively,p = 0.012) but no statistically significant relationship was seen between the expression of c-kit proto-oncogene product and other clinicopathological parameters of breast cancer, including histologic type, tumor size, lymph node metastasis, distant metastasis, stage, progesterone receptor, c-erbB-2 expression, menopausal status and age of the patient (p > 0.05).
  • CONCLUSIONS: Our results show that a high level of c-kit expression occurs frequently in invasive breast cancer, and its expression is associated with ER but unrelated to other clinico-pathological variables.
  • [MeSH-major] Breast Neoplasms / metabolism. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848740.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


22. Meller MT, Cox JE, Callanan KW: Incidental detection of breast lesions with computed tomography. Clin Breast Cancer; 2007 Jun;7(8):634-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental detection of breast lesions with computed tomography.
  • The incidental finding of a breast lesion on a computed tomography scan is increasingly common at our institution.
  • In the past 12 months, we have diagnosed 6 primary breast cancers--1 metastasis and 5 benign lesions--in this manner.
  • We describe 4 cases illustrating a range of breast pathologies, benign and malignant, which have been detected by computed tomography scans.
  • Accurate, prompt, triple assessment in a symptomatic breast clinic has proven essential to obtaining an eventual diagnosis in patients presenting via this slightly unusual route.
  • [MeSH-major] Breast Neoplasms / radiography. Incidental Findings. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Fibroadenoma / pathology. Fibroadenoma / radiography. Humans. Neoplasm Metastasis / pathology. Neoplasm Metastasis / radiography. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiography. Venous Thrombosis / complications. Venous Thrombosis / radiography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17592677.001).
  • [ISSN] 1526-8209
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Vlassov VV, Laktionov PP: Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer; 2006 May 22;94(10):1492-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation.
  • Concentration of cirDNA and methylation of RARbeta2, RASSF1A and HIC-1 gene promoters were investigated in cell-free and cell-surface-bound fractions from healthy donors, patients with breast cancer, and patients with breast fibroadenoma.
  • Analysis of RARbeta2 and RASSF1A methylation in the total cirDNA provides 95% diagnostic coverage in breast cancer patients, 60% in patients with benign lesions, and is without false-positive results in healthy women.
  • Results of the study indicate that methylation-specific PCR of RARbeta2 and RASSF1A genes based on the total cirDNA combined with the quantitative analysis of cirDNA distribution between cell-bound and cell-free fractions in blood provide the sensitive and accurate detection and discrimination of malignant and benign breast tumours.
  • [MeSH-major] Breast Neoplasms / blood. DNA Methylation. DNA, Neoplasm / blood. DNA-Binding Proteins / genetics. Fibroadenoma / blood. Receptors, Retinoic Acid / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2000 Apr;906:5-7 [10818586.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:191-6 [17108211.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):71-6 [11829433.001]
  • [Cites] Anticancer Drugs. 2002 Apr;13(4):353-7 [11984080.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5462-82 [12154408.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:217-20 [15251963.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:221-7 [15251964.001]
  • [Cites] Anal Biochem. 1980 Mar 1;102(2):344-52 [6158890.001]
  • [Cites] J Clin Invest. 1985 Dec;76(6):2182-90 [3001145.001]
  • [Cites] Mol Biol (Mosk). 1988 Nov-Dec;22(6):1667-72 [3252155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2315-24 [10325420.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3956-63 [10339505.001]
  • [Cites] Histol Histopathol. 1999 Oct;14(4):1159-64 [10506932.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(6-7):873-7 [15560075.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):389-94 [10956415.001]
  • (PMID = 16641902.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / HIC1 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  • [Other-IDs] NLM/ PMC2361269
  •  go-up   go-down


24. Nguansangiam S, Jesdapatarakul S, Tangjitgamol S: Accuracy of fine needle aspiration cytology from breast masses in Thailand. Asian Pac J Cancer Prev; 2009 Oct-Dec;10(4):623-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accuracy of fine needle aspiration cytology from breast masses in Thailand.
  • OBJECTIVE: To evaluate the accuracy and diagnostic performance of fine needle aspiration FNA cytology in diagnoses of breast masses.
  • METHODS: Women who had FNA diagnoses for breast masses and underwent subsequent histopathologic evaluation during January 2003-December 2006 were accessed from the archive of the Anatomical Pathology Department of our institution.
  • Cytologic diagnoses were classified as unsatisfactory, benign, atypical probably benign, suspicious probably malignant, and malignant, and were compared to the histopathologic diagnoses obtained from core needle biopsy, excisional biopsy, or mastectomy to give an assessment of the diagnostic performance of FNA.
  • RESULTS: A series of 190 breast masses were identified during the study period.
  • The diagnoses in the remaining 182 cases were: benign lesions in 98 (53.9%); suspicious for malignancy in 31 (17.0%); and malignant in 53 (29.1%).
  • From the subsequent histopathologic diagnoses, 6/98 cases of benign cytology turned out to be malignant lesions (false negatives); 22/31 cases of suspicious cytology were truly malignant while the other nine were benign; and only 1/53 with malignant cytology was benign (false positive), the lesion being a fibroadenoma .
  • CONCLUSIONS: FNA cytology is highly accurate for diagnosis of breast masses.
  • [MeSH-major] Breast Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. False Positive Reactions. Female. Humans. Mastectomy. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Thailand. Ultrasonography, Mammary. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827882.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


25. Rykova EIu, Skvortsova TE, Hoffmann AL, Tamkovich SN, Starikov AV, Bryzgunova OE, Permiakova VI, Warnecke JM, Sczakiel G, Vlasov VV, Laktionov PP: [Breast cancer diagnostics based on extracellular DNA and RNA circulating in blood]. Biomed Khim; 2008 Jan-Feb;54(1):94-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast cancer diagnostics based on extracellular DNA and RNA circulating in blood].
  • Extracellular DNA and RNA were extracted from blood plasma and cell surface-bound fractions of patients with breast tumors and healthy controls.
  • Methylation of at least one of these genes was found in plasma of 13% patients with benign breast fibroadenoma and in 60% of breast cancer patients.
  • Using cell-surface bound DNA as a substrate for PCR have lead to increase of gene methylation detection frequency up to 87% in fibroadenoma and 95% in breast cancer patients without false positive controls.
  • GAPDH, RASSF8, Ki-67 RNA and 18S RNA were quantified using RT-qPCR of the extracellular RNA circulating in blood of patients with breast tumors and healthy controls.
  • Results show a higher amount of RASSF8, Ki-67 RNA and 18S RNA in plasma and cell-bound fraction of patients with breast cancer compared with patients with benign tumors and healthy controls.
  • The data indicate that the specific RNA quantification in blood plasma is valuable for discrimination between cancer and benign tumors, which can be detected with high sensitivity using analysis of methylated RASSF1A, Cyclin D2 and RARbeta2 genes in extracellular circulating DNA.
  • [MeSH-major] Breast Neoplasms / blood. DNA Methylation. DNA, Neoplasm / blood. Genes, Neoplasm. RNA, Neoplasm / blood
  • [MeSH-minor] Female. Humans. Neoplasm Proteins / genetics. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18421914.001).
  • [ISSN] 2310-6972
  • [Journal-full-title] Biomedit︠s︡inskai︠a︡ khimii︠a︡
  • [ISO-abbreviation] Biomed Khim
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm
  •  go-up   go-down


26. Giri D: Recurrent challenges in the evaluation of fibroepithelial lesions. Arch Pathol Lab Med; 2009 May;133(5):713-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: The morphologic spectrum of mammary fibroepithelial lesions ranges from fibroadenoma, a common benign neoplasm, to phyllodes tumor, an uncommon lesion that can sometimes recur and metastasize.
  • CONCLUSIONS: The distinction between fibroadenoma and phyllodes tumor is usually not problematic, especially in excision specimens.
  • Morphologic predictors of local recurrence of phyllodes tumor include cellularity and cytologic atypia, mitotic activity, positive margins, infiltrative borders, fibroproliferative satellite nodules, and past history of fibroadenoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Fibroadenoma / diagnosis. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Gene Expression. Humans. Immunoenzyme Techniques. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19415945.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Number-of-references] 46
  •  go-up   go-down


27. Zhang GQ, Du J, Pang D: [Detection and clinical significance of serum proteomic patterns of breast cancers by surface enhanced laser desorption/ionization time of flight mass spectrometry]. Zhonghua Zhong Liu Za Zhi; 2006 Mar;28(3):204-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection and clinical significance of serum proteomic patterns of breast cancers by surface enhanced laser desorption/ionization time of flight mass spectrometry].
  • OBJECTIVE: To detect the serum proteomic patterns in breast cancer patients by surface enhanced laser desorption/ionization time of flight (SELDI-TOF-MS) protein chip array techniques, to screen biomarker candidates and build diagnostic models in order to evaluate their clinical significance.
  • METHODS: SELDI-TOF-MS technique and weak cation exchanger (WCX2) protein chip were used to detect the serum proteomic patterns of 38 patients with breast cancer, 33 patients with benign breast diseases and 43 normal control subjects.
  • RESULTS: Four protein peaks pattern (M2077_07, M1827_38, M2650_51 and M2060_62 mass/charge ratio [m/z]) was observed in the model I, and it could be used to distinguish breast cancer from non cancerous diseases.
  • When it was used in differential diagnosis between stage I breast cancer and benign breast diseases, the sensitivity and specificity were 84.8% (28/33) and 55.6% (5/9), respectively.
  • Another 5 peaks (M1701_48, M3116_17, M1676_88, M5890_33, M2921_02 m/z) could build the model III to distinguish stage I and stage II approximately IV breast cancers.
  • CONCLUSION: Our findings suggested that application of SELDI-TOF-MS can be of great potential for early breast cancer screening, diagnosis and preoperative staging, and deserves further studies.
  • [MeSH-major] Blood Proteins / analysis. Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Humans. Middle Aged. Neoplasm Staging. Protein Array Analysis / methods. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875606.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins
  •  go-up   go-down


28. Ceçener G, Egeli U, Tunca B, Taşdelen I, Tolunay S, Bilgel N: Importance of novel sequence alterations in the FHIT gene on formation of breast cancer. Tumori; 2007 Nov-Dec;93(6):597-603
Hazardous Substances Data Bank. L-Threonine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of novel sequence alterations in the FHIT gene on formation of breast cancer.
  • AIMS AND BACKGROUND: The character, role and impact of FHIT gene alterations, for which recent studies have shown that the gene has a role in the early stage of carcinogenesis in breast cancer, are still unclear.
  • Thus, the current study evaluated FHIT gene mutations from breast tissue of women with malignant and benign breast disease and to elucidate the frequency and type of mutations in this gene.
  • PATIENTS AND METHODS: Mutations in exons 5-9 of the FHIT gene were screened using the intronic primer pairs in 83 breast (67 malignant and 16 benign) tissue samples by single-strand conformational polymorphism and sequencing analysis.
  • RESULTS: FHIT mutations were detected in 13 of the 67 malignant cases (19.4%) and 2 of the 16 benign cases (12.5%).
  • CONCLUSIONS: Our data contribute significantly to that currently known about the presence of FHIT gene mutations on the formation of breast cancer.
  • [MeSH-major] Acid Anhydride Hydrolases / genetics. Breast Neoplasms / genetics. Breast Neoplasms / pathology. Mutation. Neoplasm Proteins / genetics
  • [MeSH-minor] Adult. Aged. Alanine. Carcinoma / genetics. Female. Fibroadenoma / genetics. Frameshift Mutation. Glutamine. Humans. Hyperplasia / genetics. Lymphatic Metastasis. Middle Aged. Phenylalanine. Polymerase Chain Reaction. Polymorphism, Single-Stranded Conformational. Sequence Analysis, DNA. Threonine

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • Hazardous Substances Data Bank. Glutamine .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338496.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; 0RH81L854J / Glutamine; 2ZD004190S / Threonine; 47E5O17Y3R / Phenylalanine; EC 3.6.- / Acid Anhydride Hydrolases; OF5P57N2ZX / Alanine
  •  go-up   go-down


29. Zhao TT, Li JG, Li YM: [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes]. Zhonghua Zhong Liu Za Zhi; 2007 Mar;29(3):206-9
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes].
  • OBJECTIVE: To evaluate the performance of 18F-FDG PET/CT in the detection of primary breast cancer, and the staging of regional lymph nodes.
  • METHODS: Twenty four females with highly suspected breast cancer, underwent PET/CT imaging of the breast preoperatively.
  • 32 breast lesions were evaluated by histology, revealing 25 breast carcinomas and 7 benign pathological changes.
  • 23 patients had histological diagnosis of the breast tumor and regional lymph nodes.
  • RESULTS: 20 of 25 breast carcinomas were successfully diagnosed by FDG-PET/CT.
  • No Tis breast carcinoma was detected.
  • 75.0% of T1 breast carcinomas were detected, and with 85.7% of stage T2, 100.0% of T3.
  • CONCLUSION: As a noninvasive technique, FDG PET/CT appears to be a useful method in staging patient with breast cancer, especially in cases in which the lesion is hard to predict by routine examination.
  • In the detection of breast lesions, PET/CT doesn't seem to have a high sensitivity, especially in early stage breast cancers.
  • The high cost and the space resolution limit its use as a routine diagnostic method of breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Lymph Nodes / pathology. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649638.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


30. Filipovski V, Banev S, Janevska V, Dukova B: Granular cell tumor of the breast: a case report and review of literature. Cases J; 2009;2:8551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the breast: a case report and review of literature.
  • A 22-year-old female patient presented with a breast mass lesion with a clinical suspicion of a fibroadenoma.
  • Histological evaluation revealed a rare benign neoplasm - granular cell tumor.Granular cell tumor is rare neoplasm that may arise in virtually any body site, and in 5% it occurs in the breast.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1992 Feb;116(2):206-8 [1733419.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1984;403(4):391-400 [6330972.001]
  • [Cites] Eur J Radiol. 1994 Nov;19(1):56-9 [7859762.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):709-11 [10782152.001]
  • [Cites] Cancer. 1953 Jul;6(4):786-9 [13059774.001]
  • [Cites] Obstet Gynecol. 1989 May;73(5 Pt 2):898-900 [2539575.001]
  • [Cites] Am J Clin Pathol. 1949 Jun;19(6):522-35 [18150636.001]
  • [Cites] J Surg Oncol. 1980;13(4):301-16 [6246310.001]
  • [Cites] South Med J. 1995 Nov;88(11):1146-8 [7481988.001]
  • [Cites] Diagn Cytopathol. 1996 Dec;15(5):403-8 [8989543.001]
  • [Cites] South Med J. 1997 Nov;90(11):1149-51 [9386062.001]
  • [Cites] Eur J Gynaecol Oncol. 2002;23(4):333-4 [12214737.001]
  • [Cites] AMA Arch Pathol. 1955 Dec;60(6):663-8 [13268207.001]
  • [Cites] Arch Pathol Lab Med. 1988 Mar;112(3):302-3 [2830865.001]
  • (PMID = 19918386.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2769456
  •  go-up   go-down


31. Li BJ, Wang JY, Wang HY, Huang XP, Zhang LJ, Long H, Yang MT, Rong TH: [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient]. Zhonghua Zhong Liu Za Zhi; 2006 Oct;28(10):766-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of hMAM mRNA detection in bone marrow of breast carcinoma patient].
  • OBJECTIVE: To investigate the expression of the human mammoglobin (hMAM) mRNA in bone marrow and its clinical significance in the breast cancer patient.
  • METHODS: Expression of hMAM mRNA was detected using nested reverse transcription polymerase chain reaction (RT-PCR) in the bone marrow aspiration sample from 75 breast cancer patients, 15 patients with benign breast lesions and 8 healthy volunteers as control.
  • The hMAM mRNA was found to be positively expressed by RT-PCR in 21 of 75 breast cancer patients with a positive rate of 28.0%.
  • However, hMAM mRNA expression was not detected in the bone marrow aspiration samples from patients with benign breast lesions and healthy volunteers.
  • The hMAM mRNA expression was positively correlated with axillary nodal involvement and progesterone receptor (PR) status (P < 0.05) as well as Ki67 expression in breast cancer tissue (chi2 = 4.936, P = 0.026), but not with age, tumor size, clinical stage, or estrogen receptor (ER) status (P > 0.05).
  • CONCLUSION: RT-PCR is quite sensitive and has a high specificity in detecting the presence of hMAM mRNA in the bone marrow from breast cancer patients.
  • Thereupon, hMAM mRNA may be useful as a molecular biomarker in detecting disseminated tumor cells (DTC) in the bone marrow of breast cancer patients.
  • [MeSH-major] Bone Marrow / metabolism. Breast Neoplasms / genetics. Breast Neoplasms, Male / genetics. Neoplasm Proteins / genetics. Uteroglobin / genetics
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / genetics. Breast / metabolism. Breast / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Female. Fibroadenoma / genetics. Fibroadenoma / pathology. Humans. Ki-67 Antigen / genetics. Lymphatic Metastasis. Male. Mammaglobin A. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Progesterone / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17366790.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Receptors, Progesterone; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


32. Weaver DL, Rosenberg RD, Barlow WE, Ichikawa L, Carney PA, Kerlikowske K, Buist DS, Geller BM, Key CR, Maygarden SJ, Ballard-Barbash R: Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography. Cancer; 2006 Feb 15;106(4):732-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic findings from the Breast Cancer Surveillance Consortium: population-based outcomes in women undergoing biopsy after screening mammography.
  • METHODS: Breast Cancer Surveillance Consortium data from 1996-2001 were used to identify pathology specimens that were obtained within 1 year of screening mammograms performed on 786,846 women ages 40-89 years.
  • The pathology results were classified as invasive carcinoma, ductal carcinoma in situ (DCIS), or benign.
  • The 1,664,032 screening mammograms were followed by 26,748 known biopsies (1.6%) and 8815 diagnoses of breast carcinoma (0.53%).
  • Most invasive tumors measured between 0 mm and 10 mm (35%) or between 11 mm and 20 mm (36%) in greatest dimension, and 92% and 78% were lymph node-negative tumors, respectively: Biopsy results that were classified as malignant increased with age (P < 0.0001) and were most likely to follow Breast Imaging, Reporting, and Diagnosis System Category 5 and 4 assessments, respectively.
  • Ductal hyperplasia (19.6%), fibroadenoma (18.5%), and other benign findings (56.1%) were the most common benign diagnoses.
  • The prevalence of invasive carcinoma, DCIS, and benign findings presented herein establish a range of expected biopsy outcomes for women after screening mammography in the general U.S. population.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16411214.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01-CA86082; United States / NCI NIH HHS / CA / U01-CA63740; United States / NCI NIH HHS / CA / U01-CA69976; United States / NCI NIH HHS / CA / U01-CA70040; United States / NCI NIH HHS / CA / U01 CA086082; United States / NCI NIH HHS / CA / U01-CA86076; United States / NCI NIH HHS / CA / U01-CA70013; United States / NCI NIH HHS / CA / U01-CA63731
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


33. Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans-Wielenga V, Rank F, Moreira JM: Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol Oncol; 2007 Dec;1(3):321-49
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease.
  • Recently, we presented evidence--based on the analysis of benign hyperproliferative lesions of the breast--for the presence of cells that express the stem cell marker cytokeratin (CK) 15 in combination with CK19, a protein widely expressed by mammary epithelial cells.
  • Here we report the finding of a subset of breast carcinomas characterized by expression of CK15.
  • CK15 expressing tumors constituted 5% (6 out of 120; 4 of ductal type and 2 of lobular type) of the high-risk breast carcinomas examined by gel-based proteomics and immunohistochemistry.
  • Cells with a very similar phenotype to the CK15+/CK19+ progenitor cells were observed in a juvenile fibroadenoma as well as in the large collecting ducts of the breast.
  • The latter, however, expressed in addition CK14 and had a phenotype (CK15+/CK19+/CK14+/CK8+ (weak)/ER-/PgR-/AR-/CD44+ (weak)/CK17-/p63-/vimentin-/Ki67-/Bcl-2+/GATA-3-/p53-) that resembled that of the putative normal adult breast stem cells as inferred from published data.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Keratin-15 / metabolism. Precancerous Conditions / pathology. Stem Cells
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Female. Fluorescent Antibody Technique, Direct. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness


34. Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES: Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. Int J Cancer; 2009 Dec 15;125(12):2887-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer.
  • The methylation status of cystatin M (CST6) gene in breast tumors was investigated and its prognostic significance as a novel breast cancer biomarker was evaluated.
  • Using methylation-specific PCR (MSP), CST6 promoter methylation was examined in 134 formalin fixed paraffin-embedded tissues (FFPEs): 10 pairs of breast tumors and their surrounding normal tissues, 10 breast fibroadenomas, 11 normal breast tissues and 93 breast tumors.
  • Methylation of CST6 promoter was observed in 2/21 (9.5%) noncancerous breast tissues, 1/10 (10%) benign breast tumors (fibroadenomas) and 52 (55.9%) operable breast cancer tumor samples.
  • CST6 promoter methylation status in tumor cells seems to provide important prognostic information in operable breast cancer and merits to be further evaluated and validated in a larger cohort of patients.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / genetics. Breast Neoplasms / surgery. Cystatin M / genetics. DNA Methylation. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Biomarkers, Tumor. Carcinoma, Lobular / genetics. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. DNA, Neoplasm / genetics. Female. Fibroadenoma / genetics. Fibroadenoma / pathology. Fibroadenoma / surgery. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Polymerase Chain Reaction. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 UICC.
  • (PMID = 19551853.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CST6 protein, human; 0 / Cystatin M; 0 / DNA, Neoplasm
  •  go-up   go-down


35. Fajdić J, Gotovac N, Hrgović Z, Kristek J, Horvat V, Kaufmann M: Phyllodes tumors of the breast diagnostic and therapeutic dilemmas. Onkologie; 2007 Mar;30(3):113-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumors of the breast diagnostic and therapeutic dilemmas.
  • PATIENTS AND METHODS: From 1991 to 2005, 2,848 breast cancer patients were treated in our institutions, 36 (1.44%) for phyllodes tumors.
  • RESULTS: Histology showed the phyllodes tumors to be benign in 27 (75.0%), malignant in 6 (16.6%), and borderline in 3 (8.3%) cases.
  • In this period, recurrences of 3 (8.3%) malignant and 2 (5.6%) benign phyllodes tumors were diagnosed and treated.
  • Problems in diagnosing this condition arise from its similarity to fibroadenoma.
  • [MeSH-major] Breast Neoplasms / diagnosis. Phyllodes Tumor / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / pathology. Diagnosis, Differential. Female. Humans. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. Mammography. Mastectomy. Mastectomy, Segmental. Middle Aged. Mitotic Index. Necrosis. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Prognosis. Reoperation. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17341897.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


36. Blohmer JU, Reinhardt M, Schmalisch G, Lichtenegger W, Hausschild M, Kümmel S, Fischer T, Ohlinger R, Thomas A: Videodensitometry in the examination of focal breast lesions after injection of an ultrasound contrast agent. Anticancer Res; 2006 Mar-Apr;26(2C):1691-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Videodensitometry in the examination of focal breast lesions after injection of an ultrasound contrast agent.
  • BACKGROUND: The present investigation aimed at assessing the possibility of distinguishing between malignant and benign breast lesions by measuring the signal intensity in vessels of the suspect lesions over time after administration of the ultrasound contrast agent Levovist.
  • MATERIALS AND METHODS: Levovist was administered intravenously to 21 patients with breast cancer and 12 patients with a benign breast lesion.
  • RESULTS: The differences between the benign and the malignant lesions for the parameters T(max) and T(90%) were statistically significant.
  • The malignant foci showed a significantly more rapid in-flow of the contrast agent (p = 0.006) than the benign lesions.
  • The wash-in wash-out time for Levovist was significantly shorter for the malignant lesions than for the benign lesions (p = 0.02).
  • The specificity and sensitivity made a more precise differentiation between benign and malignant tumors possible.
  • CONCLUSION: The use of a contrast agent in Doppler ultrasound enhances the diagnostic reliability in distinguishing between malignant and benign lesions, justifying the use of a contrast agent with a high specificity (92%) such as Levovist.
  • It is possible that the combination of Levovist and videodensitometry will make it possible to increase the specificity of breast cancer diagnosis.
  • [MeSH-major] Breast Neoplasms / diagnosis. Densitometry / methods. Polysaccharides. Video Recording / methods
  • [MeSH-minor] Contrast Media. Female. Fibroadenoma / blood supply. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Humans. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617563.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Polysaccharides; 127279-08-7 / SHU 508
  •  go-up   go-down


37. Dugina VB, Chipysheva TA, Ermilova VD, Gabbiani D, Chaponnier C, Vasil'ev IuM: [Distribution of actin isoforms in normal, dysplastic, and tumorous human breast cells]. Arkh Patol; 2008 Mar-Apr;70(2):28-31
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Distribution of actin isoforms in normal, dysplastic, and tumorous human breast cells].
  • The distribution of beta- and gamma-cytoplasmic actins was compared in the normal cells and dysplastic malignant breast epithelial cells.
  • The authors' findings suggest that specific monoclonal antibodies to beta- and gamma-cytoplasmic actins may be used as supplementary markers that can differentiate benign and malignant breast neoplasms.
  • [MeSH-major] Actins / metabolism. Breast Neoplasms / metabolism. Fibroadenoma / metabolism. Fibrocystic Breast Disease / metabolism. Mammary Glands, Human / metabolism. Neoplasm Proteins / metabolism. Papilloma / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540438.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Actins; 0 / Neoplasm Proteins; 0 / Protein Isoforms
  •  go-up   go-down


38. Akin M, Irkorucu O, Koksal H, Gonul II, Gultekin S, Kurukahvecioglu O, Anadol AZ, Tekin E: Phyllodes tumor of the breast; a case series. Bratisl Lek Listy; 2010;111(5):271-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor of the breast; a case series.
  • BACKGROUND: Phyllodes tumor (PT) is a rare neoplasm comprising less than 1% of all breast tumors.
  • Its clinical spectrum ranges from a benign and locally recurrent form of behavior to malignant and metastatic forms.
  • All cases were histologically examined by an experienced breast pathologist, and tumors were classified as benign, borderline malignant or malignant according to standard histological criteria.
  • Seven (70%) of 10 tumors were benign and 3 (30%) were malignant.
  • CONCLUSION: PT is a rare neoplasm of the breast.
  • It resembles fibroadenoma.
  • [MeSH-major] Breast Neoplasms. Phyllodes Tumor

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20568416.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


39. Djordjevic B, Hanna WM: Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon. Mod Pathol; 2008 Oct;21(10):1238-45
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon.
  • The expression of c-kit, a protooncogene tyrosine kinase receptor (CD117), in phyllodes tumors of the breast has been the subject of recent investigations.
  • We examined stromal c-kit expression by immunohistochemistry in 68 cases comprising fibroadenomas, fibroadenomas with cellular stroma, and benign, borderline, and malignant phyllodes tumors.
  • Our findings indicate that c-kit is an unlikely player in the pathogenesis of fibroepithelial lesions of the breast.
  • [MeSH-major] Breast Neoplasms / metabolism. Mast Cells / metabolism. Phyllodes Tumor / metabolism. Proto-Oncogene Proteins c-kit / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. DNA Mutational Analysis. DNA, Neoplasm / analysis. Female. Fibroadenoma / metabolism. Fibroadenoma / pathology. Humans. Immunohistochemistry. Mastectomy. Stromal Cells / metabolism. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500266.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


40. Iyengar P, Cody HS 3rd, Brogi E: Pleomorphic adenoma of the breast: case report and review of the literature. Diagn Cytopathol; 2005 Dec;33(6):416-20
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic adenoma of the breast: case report and review of the literature.
  • Pleomorphic adenoma of the breast (PAB) is a very rare neoplasm.
  • On cytologic material, fibroadenoma and phyllodes tumor should also be considered within the differential diagnosis.
  • Correct identification of this benign mammary neoplasm is important to avoid unnecessarily aggressive treatment.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Breast Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 16299746.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Yamamoto H, Okumura K, Toshima S, Mukaisho K, Sugihara H, Hattori T, Kato M, Asano S: FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues. Biol Pharm Bull; 2009 Jul;32(7):1148-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FXYD3 protein involved in tumor cell proliferation is overproduced in human breast cancer tissues.
  • FXYD3, also known as Mat-8 (Mammary tumor 8 kDa), is one of mRNAs highly expressed in mouse and human breast cancers.
  • Here, we newly found that FXYD3 protein was also overexpressed in human breast cancer specimens; invasive ductal carcinomas and intra-ductal carcinomas, whereas its expression was low in benign lesion specimens; mastopathy, fibroadenoma and phyllodes tumors.
  • Here, we found that FXYD3a mRNA is a major transcript product expressed in human normal tissues as well as in breast, colon, stomach and pancreas cancer cell lines.
  • Cell proliferation rate of MCF-7 breast cancer cell line was drastically decreased when FXYD3a and 3b mRNAs were suppressed by the small interfering RNA.
  • These results suggest that FXYD3a protein is highly expressed in breast cancers, and responsible for cancer cell proliferation.
  • [MeSH-major] Breast Neoplasms / metabolism. Cell Proliferation. Membrane Proteins / biosynthesis. Neoplasm Proteins / biosynthesis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19571376.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / FXYD3 protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


42. Iyengar P, Ali SZ, Brogi E: Fine-needle aspiration cytology of mammary adenomyoepithelioma: a study of 12 patients. Cancer; 2006 Aug 25;108(4):250-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Adenomyoepithelioma (AME) of the breast is a rare neoplasm that is characterized by a biphasic proliferation of epithelial and myoepithelial cells.
  • METHODS: The authors conducted a retrospective evaluation of cytologic findings in fine-needle aspiration biopsy (FNAB) material from 12 patients with histologically proven benign AMEs of the breast.
  • None of the patients were diagnosed originally with AME: Two tumors were classified as benign and consistent with fibroadenoma, 6 tumors were atypical, 2 tumors were suspicious for carcinoma, and 2 tumors were positive for malignant cells.
  • CONCLUSIONS: Because of the varied histology of AME, cytologic diagnosis of this neoplasm can be very challenging.
  • [MeSH-major] Adenoma / pathology. Biopsy, Fine-Needle. Breast Neoplasms / pathology. Myoepithelioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16544319.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Diebold T, Jacobi V, Scholz B, Hensel C, Solbach C, Kaufmann M, Viana F, Balzer J, Peters J, Vogl T: Value of electrical impedance scanning (EIS) in the evaluation of BI-RADS III/IV/V-lesions. Technol Cancer Res Treat; 2005 Feb;4(1):93-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The evaluation included a scaling of lesions from 1 (surely benign) up to 5 (highly suggestive for malignancy) as well as the additional notification of spots.
  • Histology revealed benign results in 138 lesions and malignant results in 118 lesions (DCIS=61, ID-Ca=51, IL-Ca=5, mucinous Ca=1).
  • Most frequent lesion types for false positives were mastopathy (55/80 FP) and fibroadenoma (21/80 FP).
  • [MeSH-major] Breast Neoplasms / pathology. Imaging, Three-Dimensional / instrumentation. Imaging, Three-Dimensional / methods. Mammography / instrumentation. Mammography / methods
  • [MeSH-minor] Electric Impedance. Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15649092.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement